Article
Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
Cancer - 1 Jul 2017
Kopp Ryan P, Stratton Kelly L, Glogowski Emily, Schrader Kasmintan A, Rau-Murthy Rohini, Russo Paul, Coleman Jonathan A, Offit Kenneth
Abstract excerpt
BACKGROUND: Patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) resulting from fumarate hydratase (FH) mutations may present with skin, uterine, and renal tumors, with each having unique pathologic features. This study investigated the association between prospectively identified suspicious pathology (SP) and FH mutations when patients were referred for genetic testing. METHODS: This was an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
